Interleukin-2 in Treating Patients With Stage III or Stage IV Kidney Cancer
Public ClinicalTrials.gov record NCT00003126. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Official title
A Randomized Controlled Phase III Adjuvant Trial of High-Dose Bolus IL-2 in Patients With High-Risk Renal Cell Carcinoma
Study identification
- NCT ID
- NCT00003126
- Recruitment status
- Completed
- Study type
- Interventional
- Phase
- Phase 3
- Lead sponsor
- Loyola University
- Other
- Enrollment
- 69 participants
Conditions and interventions
Conditions
Interventions
- Interleukin-2 Drug
Drug
Eligibility (public fields only)
- Age range
- 16 Years and older
- Sex
- All
- Healthy volunteers
- Healthy volunteers not accepted
This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.
Study timeline
- Start date
- May 31, 1997
- Primary completion
- Jul 31, 2002
- Completion
- Jul 31, 2002
- Last update posted
- Jan 3, 2017
1997 – 2002
United States locations
- U.S. sites
- 15
- U.S. states
- 11
- U.S. cities
- 14
| Facility | City | State | ZIP | Site status |
|---|---|---|---|---|
| Cancer Center and Beckman Research Institute, City of Hope | Duarte | California | 91010-3000 | — |
| USC/Norris Comprehensive Cancer Center and Hospital | Los Angeles | California | 90033-0804 | — |
| Jonsson Comprehensive Cancer Center, UCLA | Los Angeles | California | 90095-1781 | — |
| Summit Medical Center | Oakland | California | 94609 | — |
| Loyola University Medical Center | Maywood | Illinois | 60153 | — |
| Indiana University Cancer Center | Indianapolis | Indiana | 46202-5289 | — |
| Beth Israel Deaconess Medical Center | Boston | Massachusetts | 02215 | — |
| University of Michigan Comprehensive Cancer Center | Ann Arbor | Michigan | 48109-0752 | — |
| Barbara Ann Karmanos Cancer Institute | Detroit | Michigan | 48201-1379 | — |
| Norris Cotton Cancer Center | Lebanon | New Hampshire | 03756-0002 | — |
| Our Lady of Mercy Medical Center | The Bronx | New York | 10466 | — |
| Carolinas Medical Center | Charlotte | North Carolina | 28232-2861 | — |
| Earle A. Chiles Research Institute at Providence Portland Medical Center | Portland | Oregon | 97213-2967 | — |
| Vanderbilt-Ingram Cancer Center | Nashville | Tennessee | 37232-6838 | — |
| University of Texas Health Science Center at San Antonio | San Antonio | Texas | 78284-7811 | — |
Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.
About this trial record page
- What this page shows
- Public field values for ClinicalTrials.gov record NCT00003126, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
- Where the data comes from
- Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
- Last refresh
- Last update posted Jan 3, 2017 · Synced Jul 21, 2026
Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.
Open the official record
The complete protocol, eligibility criteria, and contact information for NCT00003126 live on ClinicalTrials.gov.